Bladder Carcinoma Clinical Trial
Official title:
EffectiveNess of a Multimodal preHAbilitation Program in patieNts With Bladder canCEr Undergoing Cystectomy. The ENHANCE Randomized Controlled Trial
Currently, the potential value of a multimodal prehabilitation program in bladder cancer has not been extensively studied. The investigators designed the ENHANCE study to assess the effect of a structured multimodal prehabilitation program in 154 patients with bladder cancer on the number (primary endpoint) and severity of complications within 90 days, length of hospital stay, readmissions, physical fitness, muscle strength, physical functioning, nutritional status, smoking behaviour, anxiety and depression, fatigue, quality of life, physical activity, tumor tissue characteristics, and healthcare costs.
The ENHANCE study is a multicenter, randomized controlled trial. The intervention group will participate in a prehabilitation program of 4-6 weeks before surgery, and additionally during neoadjuvant chemotherapy if applicable. The prehabilitation program consist of a tailored exercise program, nutritional support and if relevant smoking cessation and/or psychological counselling. The exercise program is under supervision of an oncology specialized physiotherapist and comprises aerobic-, resistance- and breathing- and relaxation exercises. Patients will be asked to be physically active for an additional 2 times a week for at least 30 minutes. A dietician will provide nutritional support and give dietary advice to increase protein intake to enhance the anabolic effect on muscle mass. Additionally, patients will receive a supplement containing 30 g of high quality whey-protein daily preferably before sleep and after the supervised training. Patients who score high on anxiety and depression will be offered a referral to a psychological support. Intensive counselling and nicotine replacement therapy will be offered to all patients who smoke. Patients in the intervention group will be asked to keep a diary to track unsupervised activity and to track intake of the protein supplementation. The physical activity level in both groups will be obtained via questionnaire. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Active, not recruiting |
NCT05399004 -
Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer
|
||
Recruiting |
NCT03824691 -
hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"
|
Phase 2 | |
Recruiting |
NCT04502095 -
Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy
|
Phase 4 | |
Completed |
NCT03125226 -
TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer
|
N/A | |
Withdrawn |
NCT05564416 -
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
|
Phase 2 | |
Terminated |
NCT02169284 -
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
|
Phase 2 | |
Recruiting |
NCT05519878 -
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
|
N/A | |
Active, not recruiting |
NCT02439060 -
PUBMIC (Prophylactic Use of Biologic Mesh in Ileal Conduit)
|
N/A | |
Recruiting |
NCT04410302 -
Patient-Derived Xenografts to Reduce Cancer Health Disparities
|
||
Withdrawn |
NCT04054752 -
Vaccine Response With NT-I7
|
Phase 1 | |
Terminated |
NCT03549650 -
Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms
|
Phase 2 | |
Completed |
NCT00469066 -
Cone Beam CT Scanning in Lung and Bladder Cancer.
|
N/A | |
Active, not recruiting |
NCT03757949 -
Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
|
Phase 3 | |
Completed |
NCT03064308 -
The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery
|
N/A | |
Active, not recruiting |
NCT02432963 -
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
|
Phase 1 | |
Active, not recruiting |
NCT02408406 -
PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers
|
N/A | |
Recruiting |
NCT06109857 -
Bladder Bank (a Prospective Banking Study)
|
||
Terminated |
NCT02145390 -
Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy
|
N/A | |
Terminated |
NCT01245660 -
A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy
|
Phase 0 |